MedPlus Health Services Ltd Q1 FY26 – 4,552 Stores, 59% Pledged Shares, and Margins as Thin as Disprin Strips
1. At a Glance
MedPlus, India’s second-largest pharmacy chain, is running 4,552 stores across 12 states and 1 UT – but somehow still manages an 8.5% operating margin and ~2–3% net margins. The company’s stock trades at a P/E of 56x, while promoter shares are pledged to the tune of 59%. Basically, investors are paying for a high-growth retail story but also sponsoring the promoter’s pledge-driven EMI.
2. Introduction
India’s retail pharmacy game is no longer about your neighborhood chemist shouting “medicine milega.” It’s a battle of scale, discounting, and delivery speed. At one end, you have Apollo Pharmacy with its brand recognition and deep healthcare integration. At the other, online-first players like PharmEasy trying to survive after burning investor cash.
MedPlus sits somewhere in between. Think of it as the “D-Mart of medicines” – focusing on price-sensitive middle-class Indians. They’ve scaled aggressively, crossing 4,500 stores, with Tier-2 and Tier-3 cities contributing ~35% of revenues.
But unlike D-Mart’s fat margins, MedPlus survives on wafer-thin profits. Sure, sales CAGR is healthy at 16–17%, but PAT is still barely ₹178 Cr on ₹6,190 Cr sales. That’s a 2.9% margin, meaning one paracetamol strip could swing quarterly results.
And just when things look steady, promoters pledge more than half their holding. Remember, in markets, “pledged shares” = “Sword of Damocles.” One wrong quarter and lenders will knock louder than a patient asking for free samples.
3. Business Model – WTF Do They Even Do?
MedPlus is essentially a medicine kirana store chain, but with apps, branding, and private labels sprinkled on top:
Branded Pharma (67% of sales) – Bread and butter. Chronic therapies, antibiotics, vitamins – all the usual suspects.
Branded FMCG (11%) – Soaps, baby care, toiletries – basically whatever you also pick up at Big Bazaar (RIP).
Private Label Pharma (10.5%) + Private Label FMCG (7.9%) – The margin booster. Think MedPlus-branded cough syrups and shampoos, where markups are fatter.
Diagnostics – Small but growing. Three full-service labs and 100+ collection centers. A future play, but currently pocket change.
E-commerce (5% of sales) – MedPlus Mart, Lens, and Labs. Serving 2,700+ pin codes with 2-hour delivery in metros. The Swiggy of medicine, but less dopamine rush.
The value chain is tightly controlled: 95% stores are company-owned (leased), and 80% sourcing is direct from manufacturers. This keeps working capital tight but also limits scalability vs franchise-led models.
Question: Would you rather buy medicines from a “discounted but pledged” MedPlus, or trust Apollo’s premium pharmacy aura?
Commentary: Revenue growth is crawling at 3.6% YoY. PAT looks impressive at +195%, but that’s only because last year’s base was embarrassingly low. The reality: margins are still fragile, and one drug-license suspension wipes out lakhs in revenue.
Disclaimer: This fair value range is for educational purposes only and not investment advice.
6. What’s Cooking – News, Triggers, Drama
Drug License Suspensions: In Sep 2025 alone, multiple stores (Hubli, Kurnool, Telangana) faced 3–10 day suspensions. The revenue impact is small (~₹5–10 lakh per order), but the compliance image gets bruised. Too many red flags = regulators breathing down neck.
Store Expansion: Added 108 net new stores in Q2 FY25, 71 of which were Tier-2/Tier-3. Basically, chasing Bharat while Apollo milks metros.
Private Labels: Over 1,100 products now. Contribution already 18–20% in FMCG/pharma mix. This is MedPlus’s real margin play.
Diagnostics & E-commerce: Both small today (~5% of revenue each) but key optionalities. The real question: can MedPlus fight Tata 1mg and PharmEasy in delivery speed?
Question: Do you think private label cough syrups can outshine Crocin and Dettol, or will Indians always stick to “doctor ne bola tha ye hi lena”?
